In DS mouse models, augmenting Nav1.1 expression via antisense oligonucleotides or using the TrkB receptor partial agonist LM22A-4 rescues synaptic inhibition and reduces seizures (Debanne et al., 2024). Here, SCN1A is linked to Dravet syndrome.